Lübbert, M., Wijermans, P., Kicinski, M., Chantepie, S., Velden, W. V. D., Noppeney, R., Griškevičius, L., Neubauer, A., Crysandt, M., Vrhovac, R., Luppi, M., Fuhrmann, S., Audisio, E., Candoni, A., Legrand, O., Foà, R., Gaidano, G., Lammeren-Venema, D. V., Posthuma, E., Hoogendoorn, M., Giraut, A., Antunes, S., Stevens-Kroef, M., Jansen, J., Graaf, A. D., Efficace, F., Ammatuna, E., Vilque, J. P., Wäsch, R., Becker, H., Blijlevens, N., Dührsen, U., Baron, F., Suciu, S., Amadori, S., Venditti, A., Huls, G. A. (2025). 10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group. Blood. https://doi.org/10.1182/blood-2025-1676